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Edited by Laszlo NagyAbstract Diabetes is associated with an excess risk of cardiac
events, and one of the risk factors for infarction is the ele-
vated-levels of plasminogen activator inhibitor-1 (PAI-1). To
evaluate how the molecular clock mechanism is involved in the
diabetes-induced circadian augmentation of PAI-1 gene expres-
sion, we examined the expression proﬁles of PAI-1 mRNA in
the hearts of Clock mutant mice with streptozotocin-induced dia-
betes. Circadian expression of PAI-1 mRNA was blunted to low
levels under both normal and diabetic conditions in Clock mutant
mice, although the expression rhythm was augmented in diabetic
wild-type (WT) mice. Furthermore, plasma PAI-1 levels became
signiﬁcantly higher in WT mice than in Clock mutant mice after
STZ administration. Our results suggested that the circadian
clock component, CLOCK, is involved in the diabetes-induced
circadian augmentation of PAI-1 expression in the mouse heart.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Serious adverse cardiovascular events including myocardial
infarction, sudden cardiac death and stroke have pronounced
circadian rhythmicity, reaching a peak during the morning
hours. The frequency of infarction in this time period is 1.5–
3 fold higher than that during other times of the day. Levels
of blood plasminogen activator inhibitor-1 (PAI-1), the pri-
mary physiological inhibitor of plasminogen activators, peak
during the early morning, which might explain the morning
onset of myocardial infarctions [1,2]. Maemura et al. [3] de-
scribed the circadian expression of PAI-1 mRNA in the heart
and kidneys of mice, and suggested that the circadian oscilla-
tion of PAI-1 gene expression plays an important role in the
circadian ﬂuctuation of blood ﬁbrinolytic activity. Assays in vi-*Corresponding author. Fax: +81 298 619 499.
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doi:10.1016/j.febslet.2005.05.027tro have shown that CLOCK:BMAL2 (CLIF) and CLOCK:-
BMAL1 heterodimers up-regulate human PAI-1 gene
expression via E-box (CACGTG) elements located at bp
677 to 672 and at bp 562 to 557 [3].
Clock was the ﬁrst clock gene identiﬁed in vertebrates by for-
ward mutagenesis using N-ethyl-N-nitrosourea in a behavioral
screening [4]. When transferred from a light–dark cycle to con-
stant darkness, the behavioral periodicity of homozygous
Clock mutants becomes unusually long [4,5]. Clock encodes a
basic helix–loop–helix (bHLH)-PAS transcription factor that
is a positive regulator of an autoregulatory transcription–
translation feedback loop [6]. CLOCK forms heterodimers
with BMAL1 (a bHLH-PAS transcription factor) and transac-
tivates other clock genes such as period1 (Per1), Per2, crypto-
chrome1 (Cry1), and Cry2 via E-box elements in their
promoters [6,7]. Circadian output genes such as albumin D-site
binding protein (DBP) [8,9], prokineticin 2 [10], Wee1 [11,12],
peroxisome proliferator–activated receptor a (PPARa) [13],
and Rev-erba [14] also have E-box elements in their ﬂanking re-
gions, and the rhythmic expression of these genes is CLOCK-
dependent in mammals. Therefore, whether the circadian
expression of PAI-1 mRNA is actually reduced in Clock mu-
tant mice in the same manner as that of the mPer genes,
DBP, and PPARa, should be of wide interest.
Diabetes is associated with several hematologic and rheo-
logic abnormalities that might predispose to thrombosis and
lead to an excessive risk of cardiac events. Numerous studies
have demonstrated alterations in the plasma proteins involved
in blood coagulation and ﬁbrinolysis in diabetic patients [1,15–
17]. Recent evidence suggests that increased PAI-1 production
is an important contributor to the development of vascular dis-
ease in diabetes [1,15–17]. We found that the levels of both to-
tal PAI-1 antigen and active PAI-1 antigen are increased in the
blood of mice with streptozotocin (STZ)-induced diabetes [18].
The circadian ﬂuctuation of PAI-1 mRNA expression is extre-
mely augmented in peripheral tissues such as the heart and
lungs of diabetic mice. However, the molecular mechanism
of such robust circadian PAI-1 expression in the diabetic state
has not yet been elucidated.
To evaluate how the molecular clock mechanism is involved
in the diabetes-induced circadian augmentation of PAI-1 gene
expression, we compared the expression proﬁles of PAI-1
mRNA in the hearts of wild-type (WT) and circadian rhythmblished by Elsevier B.V. All rights reserved.
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tozotocin reduces the expression of glucose transporter 2
(GLUT2) without aﬀecting proinsulin mRNA expression or
the total RNA yield and protein content in pancreatic b-cells
[19]. We also compared levels of total PAI-1 antigen in the
blood of WT and Clock mutant mice with diabetes mellitus.
The present results suggest that CLOCK, the core circadian
clock component, is involved in the diabetes-induced circadian
augmentation of PAI-1 expression in peripheral tissues, which
consequently decreases ﬁbrinolytic activity in a time-dependent
manner.2. Materials and methods
Animals. Clock mutant mice were derived from animals supplied by
J.S. Takahashi (Northwestern University, Evanston IL.) that origi-
nally had the Clock allele on BALB/c and C57BL/6J backgrounds. A
breeding colony was established by further backcrossing with Jcl:ICR
mice [5]. Male mice at 8–12 weeks of age were maintained under a
12:12 h light–dark cycle (lights on at 0:00 and lights oﬀ at 12:00). Insu-
lin-dependent diabetes was induced by a single intraperitoneal injec-
tion of the b-cell toxin streptozotocin (STZ, 200 mg/kg) as described
[20]. Twenty-six days later, the mice were sacriﬁced at 2:00, 8:00,
14:00, and 20:00 h, and tissues were dissected, quickly frozen and
stored in liquid nitrogen.
Measurement of serum glucose, insulin, and corticosterone levels.
Immediately before tissue isolation, blood was withdrawn from the
mice and centrifuged for 10 min at maximum speed in a desktop cen-
trifuge. Serum samples were collected and stored at 80 C. Humoral
factors indicating the development of diabetes were determined in
these serum samples. Serum glucose levels were measured using a kit
(Wako Pure Chemical Industries, Osaka, Japan). Serum insulin and
corticosterone (CS) levels were measured using commercially available
ELISA (Mercodia AB, Sweden) and EIA (Diagnostic Systems Labora-
tories, Inc., TX, USA) kits, respectively.
Northern blot analysis. Total RNA was extracted from tissues using
guanidinium thiocyanate followed by ISOGEN (Nippon Gene Co.,
Ltd.; Japan). Total RNA (20 lg) from tissues at each time point was
denatured, separated on 1% agarose/0.7 M formaldehyde gels, and
blotted onto nylon membranes (GeneScreen Plus; DuPont, USA) by
passive capillary transfer. The probes generated from cDNA fragments
of PAI-1 (bases: 138-689; GenBank Accession No. M33960) and DBP
(bases: 1138-1602; GenBank Accession No. J03179) were hybridized
and detected as described [21]. Samples were normalized to the amount
of GAPDH mRNA as described (data not shown) [18].
Measurement of plasma total PAI-1 levels. Blood samples were
immediately suspended in 0.2 volumes of 65 mM sodium citrate, pH
7.2 and centrifuged as described above to obtain platelet-poor plasma,
in which total PAI-1 levels were measured using a total murine PAI-1
ELISA kit (Molecular Innovations, Inc. Southﬁeld, MI).
Statistics. Data are expressed as means ± SEM. Time-dependent
variations were statistically analyzed using the one-way analysis of var-
iance (ANOVA). Group diﬀerences were tested by Students t test or
by the two-way ANOVA.3. Results
Fig. 1A and B shows that food and water intake was signif-
icantly increased after STZ administration in both WT (food,
df = 39, P < 0.01; water, df = 39, P < 0.01) and homozygous
Clock mutant (food, df = 35, P < 0.01; water, df = 35,
P < 0.01) mice. The STZ injection did not signiﬁcantly alter
the body weight of the WT and Clock mutant mice (df = 40,
P = 0.61 and df = 32, P = 0.54, respectively) (data not shown),
although both WT and Clock mutant control mice (vehicle
injection) weighed slightly but signiﬁcantly more during thestudy (df = 38, P < 0.01 and df = 38, P < 0.01, respectively;
data not shown).
Serum glucose levels averaged about 5-fold more in diabetic
than in control mice of both genotypes (WT, F[1,32] = 367,
P < 0.01; Clock, F[1,33] = 399, P < 0.01) (Fig. 1C). Serum
insulin levels varied in a circadian manner in control mice of
both genotypes (WT, F [3,16] = 7.89, P < 0.01; Clock,
F[3,16] = 3.43, P < 0.05), while the acrophase of Clock mutant
mice was delayed for several hours compared with that of WT
mice (Fig. 1D). Streptozotocin continuously decreased insulin
levels in both WT (F[1,32] = 66.0, P < 0.01) and Clock mutant
mice (F[1,33] = 15.0, P < 0.01).
The circadian expression of PAI-1 mRNA peaked in the
hearts of normal WT mice at 14:00 (F[3,15] = 15.2, P < 0.01)
(Fig. 2A). The oscillation was augmented (F[3,29] = 51.6,
P < 0.01) and the peak levels were increased about 1.8-fold
after STZ administration in WT mice (Fig. 2A). However,
rhythmic PAI-1 mRNA expression was damped in the hearts
of control Clock mutant mice (F[3,16] = 1.84, P = 0.18). The
STZ-injection increased cardiac PAI-1 mRNA levels by about
1.3-fold (F[1,32] = 13.8, P < 0.01) but the expression did not
become signiﬁcantly rhythmic (F[3,16] = 0.362, P = 0.78) in
Clock mutant mice.
On the other hand, robust circadian expression of DBP
mRNA peaked at 08:00 in the hearts of both normal and dia-
betic WT mice (F[3,15] = 105, P < 0.01 and F[3,14] = 26.2,
P < 0.01, respectively) (Fig. 2B). The expression proﬁles did
not diﬀer between normal and diabetic WT mice
(F[1,29] = 0.429, P = 0.52). However, the rhythmic expression
of DBP mRNA was completely abolished in the hearts of both
normal (F[3,16] = 0.709, P = 0.56) and diabetic
(F[3,16] = 0.529, P = 0.67) Clock mutant mice. Levels of
DBP mRNA expression did not signiﬁcantly diﬀer between
control and diabetic Clock mutant mice (F[3,32] = 0.059,
P = 0.81).
Plasma levels of total PAI-1 antigen were obviously in-
creased by STZ in both WT and Clock mutant mice
(F[1,32] = 45.1, P < 0.01 and F[1,33] = 23.8, P < 0.01, respec-
tively) (Fig. 3). Peak to peak comparisons revealed that STZ
increased the plasma PAI-1 levels from 0.85 ± 0.10 to
2.28 ± 0.35 and from 0.72 ± 0.11 to 1.31 ± 0.12 in WT and
Clock mutant mice, respectively. However, it should be noted
that the plasma PAI-1 levels were signiﬁcantly higher in the
diabetic WT mice than in the diabetic Clock mutant mice
(F[1,32] = 7.34, P < 0.05), although the levels did not statisti-
cally diﬀer between the genotypes under normal conditions
(F[1,32] = 2.30, P = 0.139). Thus, the Clock mutation dimin-
ished the diabetes-induced increase in plasma PAI-1 levels.
Serum CS levels varied in a circadian manner in control mice
of both genotypes (WT, F[3,16] = 15.4, P < 0.01; Clock,
F[3,16] = 3.50, P < 0.05), while the acrophase of Clock mutant
mice was delayed compared with that of WT mice (Fig. 4).
Streptozotocin increased CS levels in a circadian manner in
both WT (F[1,31] = 8.16, P < 0.01) and Clock mutant mice
(F[1,33] = 26.1, P < 0.01).4. Discussion
The ﬁbrinolytic system undergoes obvious changes in both
Type 1 (insulin-dependent) and Type 2 (non-insulin-depen-
Fig. 1. Eﬀects of STZ-induced diabetes on food and water intake,
serum glucose and insulin levels in WT and homozygous Clock mutant
mice. Twenty-one days after STZ injection, food and water intake was
evaluated throughout the day (n = 17–21 per group). Humoral
markers of diabetes were examined in serum samples (n = 4–6 per
group) obtained from decapitated mice (see Section 2). Horizontal
open and dark bars indicate lights-on and lights-oﬀ, respectively.
Values are means ± SEM. Open and ﬁlled circles indicate values for
control (CTRL) and STZ-injected WT mice, respectively. Open and
ﬁlled squares indicate values for control (CTRL) and STZ-injected
Clock mutant (Clk/Clk) mice, respectively.
Fig. 2. Temporal expression of PAI-1 and DBP mRNAs in the hearts
of WT and homozygous Clock mutant mice with STZ-induced
diabetes. Animals were killed at time points indicated above blots.
Messenger RNA levels of genes were quantiﬁed from Northern blots
(n = 4–6 each). Horizontal open and dark bars indicate lights-on and
lights-oﬀ, respectively. Maximum value of control (CTRL) WT mice is
expressed as 100%. Values are means ± SEM. Open and ﬁlled circles
indicate values for CTRL and STZ-injected WT mice, respectively.
Open and ﬁlled squares indicate values for control (CTRL) and STZ-
injected Clock mutant (Clk/Clk) mice, respectively.
Fig. 3. Circadian ﬂuctuation of plasma total PAI-1 levels in WT and
homozygous Clock mutant mice with STZ-induced diabetes. Values
are means ± SEM (n = 4–6 per group). Open and ﬁlled circles indicate
values for control (CTRL) and STZ-injected WT mice, respectively.
Open and ﬁlled squares indicate values for control (CTRL) and STZ-
injected Clock mutant (Clk/Clk) mice, respectively.
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elevated in the plasma of Type 2 diabetic patients [22,23], the
eﬀects of Type 1 diabetes mellitus on plasma PAI-1 levels are
controversial. Some reports indicate that plasma PAI-1 levels
are increased in Type 1 diabetic patients [24–27], whereas oth-
ers indicate normal levels [22,28–30]. However, the molecular
mechanism of diabetes-induced PAI-1 expression has not been
elucidated.
To evaluate how the molecular clock mechanism is involved
in the diabetes-induced circadian augmentation of PAI-1 gene
expression, we examined the expression proﬁles of PAI-1
mRNA in the hearts of Clock mutant mice with STZ-induced
diabetes. The cardiac levels of PAI-1 mRNA expression and
the plasma PAI-1 levels were signiﬁcantly increased in the dia-
betic WT mice. Surprisingly, the circadian augmentation of
cardiac PAI-1 expression was suppressed in STZ-injected
Clock mutant mice, suggesting that the transcription factor
CLOCK is involved in the diabetes-induced circadian increase
in plasma PAI-1 levels. We also found that the circadian
expression of DBP mRNA was not aﬀected by STZ-induced
diabetes in mice as found in diabetic rats [31], although the cir-
cadian expression of DBP mRNA [8,9] as well as that of PAI-1
[3,32,33] is positively regulated by CLOCK via the E-box ele-
ment. These results indicated that the circadian transcription
mechanisms of the PAI-1 and DBP genes diﬀer at least under
diabetic conditions, although CLOCK is involved in the circa-dian transactivation of both genes. Recent studies have re-
vealed that class I (b) bHLH-PAS proteins such as BMAL1
(MOP3/ARNT3/TIC) and BMAL2 (CLIF/MOP9), as well as
class II (a) bHLH-PAS proteins such as CLOCK and MOP4
(NPAS2) are involved in the E-box-dependent circadian trans-
activation of mammalian clock and clock-regulated output
Fig. 4. Serum corticosterone levels in WT and homozygous Clock
mutant mice with STZ-induced diabetes. Values are means ± SEM
(n = 4–6 per group). Open and ﬁlled circles indicate values for control
(CTRL) and STZ-injected WT mice, respectively. Open and ﬁlled
squares indicate values for control (CTRL) and STZ-injected Clock
mutant (Clk/Clk) mice, respectively.
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contribute to the gene-speciﬁc transcriptional regulation via
the E-box elements under various physiological conditions
such as diabetes.
We could not exclude the possibility that the diabetes-
induced circadian augmentation of PAI-1 expression was
caused by a CLOCK-regulated indirect mechanism, because
the transcription of PAI-1 mRNA is regulated by multiple sig-
nals such as those from insulin precursors (proinsulin and split
proinsulin) [34–36], glucose [37], lipids [38], reactive oxygen
species [39], glucocorticoids [40], and inﬂammatory mediators
such as transforming growth factor b (TGFb), tumor necrosis
factor a (TNFa), and interleukin-1a (IL-1a) [41–43].
Glucocorticoid is a major inducer of PAI-1 expression in
obvious cells and tissues [40,44,45]. In fact, the cis-acting glu-
cocorticoid response element is located in the 5 0-ﬂanking se-
quence of the PAI-1 gene [40]. We previously suggested that
hypercorticosteronemia in STZ-induced diabetic mice causes
a tissue- and time-dependent increase in PAI-1 expression
[18]. However, serum CS levels in the present study were in-
creased in a circadian manner both in WT and in Clockmutant
mice. These observations suggest that CLOCK-regulated cir-
cadian augmentation of PAI-1 mRNA expression in diabetic
mice is independent of the increase in serum CS levels.
PAI-1 mRNA expression is induced by various humoral fac-
tors such as IL-1a, TNF-a, and TGF-b not only in cardiovas-
cular cells but also in cardiac myocytes [43,46,47]. This acute
induction of PAI-1 mRNA expression was thought to locally
elevate PAI-activity in the heart [47]. However, our present re-
sults are not suﬃciently complete to indicate whether or not
STZ-induced PAI-1 mRNA expression is speciﬁc for some car-
diac regions. An immunohistochemical approach should eval-
uate the region-speciﬁc PAI-1 induction in the heart of diabetic
mice.
It should be noted that in the diabetic mice, plasma PAI-1
levels peaked during the early night (Fig. 3), whereas these lev-
els are increased during the early morning in humans [1,2]. Cir-
cadian expression of PAI-1 mRNA is directly regulated by
circadian clock molecules in peripheral tissues [3]. Recent stud-
ies of circadian gene expressions in circulating blood mononu-
clear cells have revealed that peripheral circadian clocks
oscillate in an antiphasic manner between nocturnal rodents
[48] and diurnal humans [49]. Antiphasic circadian expression
of PAI-1 mRNA between nocturnal rodents and humans
might result from the antiphasic circadian activation ofCLOCK-dependent transcription as well as that of Per2
mRNA in peripheral mononuclear leukocytes [48,49]. Consid-
ering that the phase of peripheral clocks is quite diﬀerent be-
tween nocturnal rodents and humans, the increase in plasma
PAI-1 levels during the early evening in mice might explain
the high incidence of myocardial infarction in diabetic
humans.
Recent molecular dissection of the circadian clock has re-
vealed that the CLOCK-regulated circadian transactivation
of clock or clock-controlled output genes plays an important
role in the various physiological rhythms that are related to
some diseases. The core circadian components PER2 and
CRY1 are involved in tumor progression by inhibiting the
expression of hypoxia-induced vascular endothelial growth
factor (VEGF) mRNA in a circadian fashion [50]. The present
study is the ﬁrst to suggest that a positive component of the
circadian autoregulatory feedback loop, CLOCK, is involved
in the cardiovascular disorders associated with diabetes melli-
tus by aﬀecting the circadian expression of PAI-1 mRNA. The
half-life of PAI-1 in circulating blood is relatively short [51],
suggesting that de novo synthesis of PAI-1 is important. The
molecular elucidation of circadian PAI-1 expression in diabe-
tes should bring about new insight into the mechanism of ﬁbri-
nolytic disorders in diabetic patients.
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